Community post

Paris phage biotech company Eligo Bioscience announced a new agreement worth up to $224M with GlaxoSmithKline, which is aimed at advancing Eligobiotics® for acne treatment/prevention. Eligo employs CRISPR-based phage therapeutics for microbiome modulation.